SecBot SecBot
144 ·Filed Sep 11, 2026

ISCO

International Stem Cell CORP
NEUTRAL
Impact 2/10
Horizondays Processed1mo ago SEC0001949846-26-000580
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine, small-dollar director sale with no material impact. Monitor for any subsequent Form 4 filings to confirm execution, but no trading action is warranted based on this notice alone.

DirectionNeutral
Confidencemedium
Horizondays
Latest settled — T+20d
ISCO ▼ -22.22% at T+20d
NEUTRAL call -22.22% · α vs SPY -24.34% · entry $0.3600 → $0.2800
Next anchor: T+60d in 6w
Latest observation: T+30 -68.88% FF3 residual α
Entry = T+0 close
Sep 11, 2026
via day close
T+1d
+5.56%
call +5.56% · α +6.00%
$0.3800
settled 6w ago
T+5d
-8.33%
call -8.33% · α -8.11%
$0.3300
settled 6w ago
T+20d
-22.22%
call -22.22% · α -24.34%
$0.2800
settled 18d ago
T+60d
Pending
in 6w

Price Chart

Loading chart...

Executive Summary

Director Paul V. Maier filed a Form 144 notice of intent to sell 32,802 shares of International Stem Cell Corp (ISCO) on September 11, 2026, with an estimated market value of $11,808. The shares were acquired through stock grants between 2014 and 2017 as equity compensation. This is a small, routine sale by a director, representing a modest dollar amount relative to typical OTC-listed micro-cap companies, and carries limited signaling value for the stock's near-term direction.

Key Facts

  • Director Paul V. Maier filed Form 144 to sell 32,802 shares of ISCO.
  • Estimated aggregate market value of the proposed sale is $11,808.
  • Shares were acquired via stock grants between September 2014 and June 2017 as equity compensation.
  • The sale is proposed to occur on the OTC market.

Financial Impact

Proposed sale of 32,802 shares valued at approximately $11,808 — a small, non-material amount for a micro-cap issuer.

dilution

Risk Factors

  • Insider selling may signal reduced conviction, though the small size and director role limit concern.
  • OTC-listed micro-cap stocks carry elevated liquidity and volatility risk.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001949846-26-000580
Document: 0001949846-26-000580-index.html0001949846-26-000580
Document: 0001949846-26-000580.txt0001949846-26-000580
3 reports for ISCO
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for ISCO — sortable, filterable
TypeNow
Sep 11, 2026
6w ago
144
NEUTRAL ★ 2/10
$0.3600awaiting T+60—$0.1400 (−61.11%)
Sep 8, 2026
6w ago
8-K
MIXED ★ 6/10
$0.3700awaiting T+60—$0.1400 (−62.16%)
Jul 15, 2026
14w ago
8-K
BULLISH ★ 6/10
$0.2100 $0.2800▲ +33.33%▲ +29.37%$0.1400 (−33.33%)
Showing 3 of 3

US Market Status

Market Closed — Opens in 3h 14m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 11, 2026